Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)

Takuya Higashiyama,Kiminori Sugino,Hisato Hara,Ken-ichi Ito, Noriaki Nakashima,Naoyoshi Onoda,Masayuki Tori,Hiroshi Katoh,Naomi Kiyota,Ichiro Ota,Nobuyasu Suganuma,Yatsuka Hibi,Toshimitsu Nemoto,Shunji Takahashi,Katsunari Yane,Tetsuya Ioji,Shinsuke Kojima,Hideaki Kaneda,Iwao Sugitani,Makoto Tahara

European Journal of Cancer（2022）

引用 12|浏览27

暂无评分

摘要

•This study assessed the efficacy and safety of lenvatinib in unresectable ATC.•The estimated 1-year overall survival rate was 11.9%.•The estimated 1-year progression free survival rate was 4.9%.•The objective response rate was 11.9%, and the disease control rate was 73.8%.•No fatal haemorrhagic side-effect was observed.

查看译文

关键词

Anaplastic thyroid carcinoma,Thyroid,Tyrosine kinase inhibitor,Clinical trial,Lenvatinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要